Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials.

Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC.

BMJ. 2008 Mar 22;336(7645):645-51. doi: 10.1136/bmj.39472.580984.AE. Epub 2008 Feb 25. Review. Erratum in: BMJ. 2009;339:b2951.

2.

Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors.

Feringa HH, Karagiannis SE, Chonchol M, Vidakovic R, Noordzij PG, Elhendy A, van Domburg RT, Welten G, Schouten O, Bax JJ, Berl T, Poldermans D.

J Am Soc Nephrol. 2007 Jun;18(6):1872-9. Epub 2007 May 2.

3.

Meta-analysis: the effect of statins on albuminuria.

Douglas K, O'Malley PG, Jackson JL.

Ann Intern Med. 2006 Jul 18;145(2):117-24. Review.

PMID:
16847294
4.

Statins for improving renal outcomes: a meta-analysis.

Sandhu S, Wiebe N, Fried LF, Tonelli M.

J Am Soc Nephrol. 2006 Jul;17(7):2006-16. Epub 2006 Jun 8. Review.

5.

The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.

Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, van Gilst WH, de Jong PE, de Jong-van den Berg LT; PREVEND study group.

Nephrol Dial Transplant. 2006 Nov;21(11):3106-14. Epub 2006 May 23.

PMID:
16720593
6.

An overview of statin-associated proteinuria.

Tiwari A.

Drug Discov Today. 2006 May;11(9-10):458-64. Review.

PMID:
16635810
7.

Effects of statins on renal function.

Agarwal R.

Am J Cardiol. 2006 Mar 1;97(5):748-55. Epub 2006 Jan 11. Review.

PMID:
16490450
8.

In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients.

Panichi V, Paoletti S, Mantuano E, Manca-Rizza G, Filippi C, Santi S, Taccola D, Donadio C, Tramonti G, Innocenti M, Casto G, Consani C, Sbragia G, Franzoni F, Galetta F, Panicucci E, Barsotti G.

Nephrol Dial Transplant. 2006 Feb;21(2):337-44. Epub 2005 Oct 25.

PMID:
16249194
9.

Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease.

Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC.

Circulation. 2005 Jul 12;112(2):171-8. Epub 2005 Jul 5.

10.

Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?

Campese VM, Nadim MK, Epstein M.

J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S11-7. Review.

11.

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.

Arch Intern Med. 2005 Apr 25;165(8):936-46.

PMID:
15851647
12.

Effect of pravastatin on cardiovascular events in people with chronic kidney disease.

Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M.

Circulation. 2004 Sep 21;110(12):1557-63. Epub 2004 Sep 13. Review.

13.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program.

J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. Review.

14.
15.

Cholesterol and the risk of renal dysfunction in apparently healthy men.

Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM.

J Am Soc Nephrol. 2003 Aug;14(8):2084-91.

16.

Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.

Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC; Cholesterol and Recurrent Events Trial Investigators.

J Am Soc Nephrol. 2003 Jun;14(6):1605-13.

18.

Study of Heart and Renal Protection (SHARP).

Baigent C, Landry M.

Kidney Int Suppl. 2003 May;(84):S207-10. Review.

PMID:
12694346
19.

A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

Bianchi S, Bigazzi R, Caiazza A, Campese VM.

Am J Kidney Dis. 2003 Mar;41(3):565-70. Erratum in: Am J Kidney Dis. 2004 Jan;43(1):193.

PMID:
12612979
20.

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

JAMA. 2002 Dec 18;288(23):2998-3007.

PMID:
12479764

Supplemental Content

Support Center